Reports Q4 revenue $476.1M, consensus $447.91M. “We had a strong finish to the year, with excellent performance across the board,” said Steve Chapman, chief executive officer of Natera (NTRA). “Our ongoing success can be attributed to the mission-driven mindset of our team and our focus on patients. We have significant momentum, with several potential catalysts in 2025 and beyond.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera’s Strong Market Position and Growth Potential Drive Buy Rating Amid Expanded Medicare Coverage and Robust Patent Protections
- Natera announces Medicare coverage of Signatera test
- Is NTRA a Buy, Before Earnings?
- Natera comments on updated NCCN guidance for circulating tumor DNA
- Natera’s Promising RhD Test Developments and Revenue Growth Potential: A Buy Recommendation